Frontlight ResearchEarly access
Kidney cancer trials in Spain
30 of 36 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Where
- Barcelona
- Age
- 18 years and over
- People
- 512 worldwide
- Run by
- Arcus Biosciences, Inc.
See details and how to joinNCT05536141 · EU 2024-519142-70-00 - Phase 3Taking peopleA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
- Where
- Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Sevilla, Valencia
- Age
- 18 years and over
- People
- 758 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07489495 · EU 2024-516993-31-00 - Phase 1Taking peopleA Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Logroño, Madrid
- Age
- 18 years and over
- People
- 124 worldwide
- Run by
- Pliant Therapeutics, Inc.
See details and how to joinNCT06270706 - Phase 3Taking peopleA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Where
- Barcelona, Córdoba, Girona, L'Hospitalet de Llobregat, Madrid, Santander, Valencia
- Age
- 18 years and over
- People
- 904 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07227402 · EU 2024-517136-21-00 - Phase 2Not yet taking people in SpainPembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
- Where
- Barcelona, Córdoba, L'Hospitalet de Llobregat, Lugo, Madrid, Ourense, Oviedo, Pamplona, Sabadell, Santander, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 150
- Run by
- Vall d'Hebron Institute of Oncology
See details and how to joinNCT07593040 · EU 2024-519673-18-00 - Phase 3Taking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 - Phase 1Taking peoplePhase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Where
- Madrid
- Age
- 18 years and over
- People
- 130 worldwide
- Run by
- Sairopa B.V.
See details and how to joinNCT05856981 - Phase 3Taking peopleStudy of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Where
- Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Pamplona, Pozuelo de Alarcón, Sabadell, Santander, Sevilla, Valencia, Vigo
- Age
- 18 years and over
- People
- 720 worldwide
- Run by
- Arcus Biosciences, Inc.
See details and how to joinNCT07011719 · EU 2024-515023-11-00 - Phase 1/2Taking peopleSubstudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
- Where
- Barcelona, Madrid
- Age
- 18 years to 120 years
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07049926 · EU 2024-516437-12-00 - Phase 1/2Not yet taking people in SpainA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Where
- Madrid, Sevilla
- Age
- 18 years and over
- People
- 474 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07293351 · EU 2026-527163-15-00 - Phase 1Taking peopleKO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Where
- Barcelona, Madrid, Sevilla
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Kura Oncology, Inc.
See details and how to joinNCT06026410 · EU 2024-513285-19-00 - Phase 1/2Taking peopleSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Where
- Barcelona, Madrid, Málaga
- Age
- 18 years and over
- People
- 224 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227415 · EU 2025-523524-53-00 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Badajoz, Barcelona, Madrid, Pamplona, Santander, Sevilla, Valencia
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 1/2Taking peopleStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
- Where
- Lleida
- Age
- 18 years and over
- People
- 75 worldwide
- Run by
- Oncorena AB
See details and how to joinNCT05287945 - Phase 1Not yet taking people in SpainA Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
- Where
- Madrid
- Age
- 18 years and over
- People
- 112 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07848295 - Phase 3Not yet taking people in SpainCARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
- Where
- Barakaldo, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Murcia, Ourense, Sabadell, Santander, Santiago De Compostela, Valencia, Valladolid, Vigo
- Age
- 18 years and over
- People
- 1,373 worldwide
- Run by
- Institut Gustave Roussy
See details and how to join2023-503317-29-00 - Phase 1/2Taking peopleKidney cancer
- Where
- Lleida, Madrid
- Age
- 18 years and over
- People
- 105 worldwide
- Run by
- Oncorena AB
See details and how to join2023-505605-16-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 1Taking peopleA First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Where
- Barcelona, Córdoba
- Age
- 18 years and over
- People
- 281 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07195682 · EU 2025-522543-18-00 - Phase 1Taking peopleStudy of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 307 worldwide
- Run by
- Xencor, Inc.
See details and how to joinNCT05433142 · EU 2024-513619-28-00 - Phase 2Not yet taking people in SpainGenitourinary Tumors With Sacituzumab Tirumotecan
- Where
- Madrid
- Age
- 18 years and over
- People
- 100
- Run by
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
See details and how to joinNCT07716917 · EU 2026-526048-10-00 - Phase 1Taking peopleStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Where
- L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 248 worldwide
- Run by
- Calico Life Sciences LLC
See details and how to joinNCT04777994 · EU 2023-507568-38-00 - Phase 2Taking peopleRadiopharmaceutical Treatment of Advanced Kidney Cancer
- Where
- Barcelona, Madrid
- Age
- 18 years to 100 years
- People
- 48 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT06783348 · EU 2024-517899-38-00 - Phase 2Active, not recruitingPhase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- Where
- A Coruña, Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Advenchen Pharmaceuticals, LLC.
See details and how to joinNCT05363280 · EU 2023-509067-24-01 - Phase 1/2Not yet taking people in SpainA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Where
- Barcelona, Madrid, Sevilla, Valencia
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06413680 · EU 2025-523399-22-00